{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:24:39Z","timestamp":1788452679416,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.annder.2025.103352","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T19:56:08Z","timestamp":1741722968000},"page":"103352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Value of tacrolimus 0.1% in the treatment of vitiligo in the era of targeted therapy"],"prefix":"10.1016","volume":"152","author":[{"given":"A.","family":"Duplaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tannous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Passeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Quereux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Chosidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2025.103352_b0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Vitiligo Lancet"},{"key":"10.1016\/j.annder.2025.103352_b0010","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","article-title":"Global vitiligo atlas. Estimating the burden of vitiligo: a systematic review and modelling study","volume":"9","author":"Akl","year":"2024","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.annder.2025.103352_b0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/pde.12226","article-title":"Quality of life impairment in children and adolescents with vitiligo","volume":"31","author":"Silverberg","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2133.2009.09091.x","article-title":"Willingness-to-pay and quality of life in patients with vitiligo","volume":"161","author":"Radtke","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0025","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bjd.15560","article-title":"Factors affecting quality of life in patients with vitiligo: a nationwide study","volume":"178","author":"Bae","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0030","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1067\/mjd.2001.113475","article-title":"Oral dexamethasone pulse treatment for vitiligo","volume":"44","author":"Radakovic-Fijan","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2310\/7750.2013.12053","article-title":"Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo","volume":"17","author":"Kanwar","year":"2013","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.annder.2025.103352_b0040","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opzelura."},{"key":"10.1016\/j.annder.2025.103352_b0045","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"TRuE-V Study Group. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2025.103352_b0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2019.07.108","article-title":"The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis","volume":"82","author":"Chang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0055","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ajd.13096","article-title":"The efficacy and safety of tacrolimus as mono\u2010and adjunctive therapy for vitiligo: a systematic review of randomised clinical trials","volume":"61","author":"Arora","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0060","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0065","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jid.2020.12.028","article-title":"Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study","volume":"141","author":"Seneschal","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0070","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/archderm.142.2.252","article-title":"Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure","volume":"142","author":"Ostovari","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40257-013-0020-1","article-title":"Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice","volume":"14","author":"Siegfried","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/jamadermatol.2021.0345","article-title":"Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis","volume":"157","author":"Lam","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0085","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","article-title":"Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis","volume":"72","author":"Legendre","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0090","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2147\/CLEP.S331287","article-title":"Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: final results from the extension of the cohort study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)","volume":"13","author":"Arana","year":"2021","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.annder.2025.103352_b0095","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jaad.2021.01.067","article-title":"The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo","volume":"84","author":"Ju","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0105","first-page":"185","article-title":"Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis","volume":"6","author":"Krueger","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.annder.2025.103352_b0110","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.18.01223","article-title":"Markedly reduced risk of internal malignancies in patients with vitiligo: a nationwide population-based cohort study","volume":"37","author":"Bae","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2025.103352_b0115","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force. Part 1: towards a new management algorithm","volume":"37","author":"Van Geel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2025.103352_b0120","unstructured":"https:\/\/www.legifrance.gouv.fr\/eli\/loi\/2020\/12\/14\/ECOX2023815L\/jo\/texte."},{"key":"10.1016\/j.annder.2025.103352_b0125","unstructured":"https:\/\/ansm.sante.fr\/actualites\/decision-du-21-03-2024-cadre-de-prescription-compassionnelle-de-tacrolimus-0-1-pommade."}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963825000110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963825000110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T23:36:08Z","timestamp":1748648168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963825000110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0151963825000110"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2025.103352","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Value of tacrolimus 0.1% in the treatment of vitiligo in the era of targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2025.103352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103352"}}